个性化文献订阅>文章检索

文章名     作者     期刊名     摘要     卷     期         如果没有找到您所需要的文献，请点击 ——此处申请     共13条记录   Tumor heterogeneity and strategies to overcome kinase inhibitor resistance in cancer: lessons from melanoma [作者：Rebecca, VW; Smalley, KSM,期刊：Expert opinion on investigational drugs, 页码：137-140 , 文章类型： Editorial Material，,卷期：2011年20-2] Lenalidomide in the treatment of chronic lymphocytic leukemia [作者：Gentile, M; Recchia, AG; Vigna, E; Mazzone, C; Lucia, E; Gigliotti, V; Bossio, S; Madeo, A; Morabito, L; Servillo, P; Franzese, S; Caruso, N; De Stefano, L; Bisconte, MG; Gentile, C; Morabito, F,期刊：Expert opinion on investigational drugs, 页码：273-286 , 文章类型： Editorial Material，,卷期：2011年20-2] Introduction: Insights into the role of the tumor microenvironment and of immune dysfunction in chronic lymphocytic leukemia (CLL) have opened the way for further augmenting the therapeutic armamentarium for CLL patients... Vorinostat in acute myeloid leukemia and myelodysplastic syndromes [作者：Prebet, T; Vey, N,期刊：Expert opinion on investigational drugs, 页码：287-295 , 文章类型： Editorial Material，,卷期：2011年20-2] Introduction: The results of conventional treatment for acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) remain poor and innovative strategies are warranted. With this aim, epigenetic modulation became a ... AMG 386: profile of a novel angiopoietin antagonist in patients with ovarian cancer [作者：Robson, EJD; Ghatage, P,期刊：Expert opinion on investigational drugs, 页码：297-304 , 文章类型： Editorial Material，,卷期：2011年20-2] Introduction: Ovarian cancer is the second most common gynecologic malignancy in the world with the majority of women presenting with advanced disease; whilst chemotherapeutic advances have improved progression-free surv... The use of single-agent dasatinib in molecularly unselected non-small-cell lung cancer patients [作者：Kruser, TJ; Traynor, AM; Wheeler, DL,期刊：Expert opinion on investigational drugs, 页码：305-307 , 文章类型： Editorial Material，,卷期：2011年20-2] A Phase II study of the Src family kinase (SFK) inhibitor dasatinib was recently reported in molecularly unselected patients with metastatic NSCLC. SFK inhibition has a strong rationale as a clinical strategy in NSCLC. T... Pharmacological small molecules for the treatment of lysosomal storage disorders (vol 19, pg 1367, 2010) [作者：Smid, BE; Aerts, JMFG; Boot, RG; Linthorst, GE; Hollak, CEM,期刊：Expert opinion on investigational drugs, 页码：309-309 , 文章类型： Correction，,卷期：2011年20-2] Targetable molecular pathways in classical Hodgkin's lymphoma [作者：Adams, H; Obermann, EC; Dirnhofer, S; Tzankov, A,期刊：Expert opinion on investigational drugs, 页码：141-151 , 文章类型： Review，,卷期：2011年20-2] Introduction: Most patients with classical Hodgkin's lymphoma (cHL) are cured by stage-adapted multimodal regimens. However, some will suffer from refractory disease or experience a relapse. Furthermore, late toxicity du... Mechanisms of drug resistance in kinases [作者：Barouch-Bentov, R; Sauer, K,期刊：Expert opinion on investigational drugs, 页码：153-208 , 文章类型： Review，,卷期：2011年20-2] Introduction: Because of their important roles in disease and excellent 'druggability', kinases have become the second largest drug target family. The great success of the BCR-ABL inhibitor imatinib in treating chronic m... Novel mitogen-activated protein kinase kinase inhibitors [作者：Chapman, MS; Miner, JN,期刊：Expert opinion on investigational drugs, 页码：209-220 , 文章类型： Review，,卷期：2011年20-2] Introduction: The development of new drugs over the last few decades has targeted specific proteins thought to be a key to the disease state. MAPK kinases 1 and 2 (commonly known as MEK1-2) represent such proteins as the... Sex hormones and lipoprotein(a) concentration [作者：Gaeta, G; Lanero, S; Barra, S; Silvestri, N; Cuomo, V; Materazzi, C; Vitagliano, G,期刊：Expert opinion on investigational drugs, 页码：221-238 , 文章类型： Review，,卷期：2011年20-2] Introduction: Increased level of lipoprotein(a) (Lp(a)) constitutes an emerging, independent risk factor for coronary artery disease. Recently, it has been recommended to lower increased (> 50 mg/dl) Lp(a) concentration.... Developments in antivirals against influenza, smallpox and hemorrhagic fever viruses [作者：Narayanan, A; Bailey, C; Kashanchi, F; Kehn-Hall, K,期刊：Expert opinion on investigational drugs, 页码：239-254 , 文章类型： Review，,卷期：2011年20-2] Introduction: The search for effective inhibitors to multiple infectious agents including influenza, smallpox and hemorrhagic fever viruses is an area of active research as many of these agents pose dramatic health and e... Effects of specific chemical suppressors of plasminogen activator inhibitor-1 in cardiovascular diseases [作者：Suzuki, J; Ogawa, M; Muto, S; Itai, A; Hirata, Y; Isobe, M; Nagai, R,期刊：Expert opinion on investigational drugs, 页码：255-264 , 文章类型： Review，,卷期：2011年20-2] Introduction: Plasminogen activator inhibitor-1 (PAI-1) is critical in thrombus formation and inflammation. Although these are essential pathological features of cardiovascular diseases, the effects of PAI-1 inhibition a... Mipomersen, an antisense apolipoprotein B synthesis inhibitor [作者：Bell, DA; Hooper, AJ; Burnett, JR,期刊：Expert opinion on investigational drugs, 页码：265-272 , 文章类型： Editorial Material，,卷期：2011年20-2] Introduction: Mipomersen is a second-generation antisense oligonucleotide (ASO) targeted to human apolipoprotein (apo) B-100, a large protein synthesized by the liver that plays a fundamental role in human lipoprotein me...